Ofatumumab demonstrates superiority over Aubagio® for relapsing MS: industry news round-up
Musculoskeletal disorders are injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.
In this week’s industry news round-up, we cover the latest headlines on two monoclonal antibodies – ofatumumab and eculizumab – for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). We also cover the approval of istradefylline as an add-on drug to treat ‘OFF’ episodes for Parkinson’s disease. Click on the titles below to navigate to each industry highlight: Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple sclerosis Eculizumab approved by the European Commission for neuromyelitis optica spectrum disorder Istradefylline approved as new add-on drug to treat 'OFF' episodes for Parkinson’s disease Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple...
